Physician profile
Shirin Esmail
NPI 1124209671
$1,571.42
in general payments reported to CMS, 2019-2025
7 companies · $486 in 2025
The $486 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $13.17 · 2021: $23.52 · 2022: $344 · 2023: $366 · 2024: $154 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.28 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $591.25 | 2019-2025 | Acuvue |
| Coopervision INC. | $520.04 | 2022-2025 | Clariti Contact Lens, Myday Contact Lens |
| Oyster Point Pharma, INC. | $171.40 | 2022 | |
| Alcon Vision LLC | $126.63 | 2022-2025 | Rhopressa, Rocklatan |
| Dompe US, INC. | $80.51 | 2023 | Oxervate |
| Bausch & Lomb Americas INC. | $42.04 | 2022-2024 | Miebo |
| Sun Pharmaceutical Industries INC. | $39.55 | 2022-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirin Esmail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.